Optimization of conventional therapy in patients with IBD. - Wikidata - awgldk - TriplyDB

Optimization of conventional therapy in patients with IBD.

Optimization of conventional therapy in patients with IBD.

http://www.wikidata.org/entity/Q37942292

about

Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Classical and recent advances in the treatment of inflammatory bowel diseases Pregnane X receptor as a target for treatment of inflammatory bowel disorders International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) mice Live Combined Bacillus subtilis and Enterococcus faecium Ameliorate Murine Experimental Colitis by Immunosuppression Prom1 function in development, intestinal inflammation, and intestinal tumorigenesis Activation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitis Select a suitable treatment strategy for Crohn's disease: step-up or top-down.Histological healing after infliximab induction therapy in children with ulcerative colitis Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.Therapy of steroid-resistant inflammatory bowel disease.Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune en Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease.The future developments in inflammatory bowel disease care.Histological healing in inflammatory bowel disease: a still unfulfilled promise.

P2860

Q26743907-95601827-5537-4973-B51C-8A492EF87030 Q26829488-BF0874EB-542D-4C88-9F75-5EFBFC914014 Q26861725-A393A52E-A01B-47BE-85F3-2BB5B0F0E88D Q26998347-0B63FAC7-1942-48CF-BD4D-B4079B6E24D0 Q28081406-54A7D80E-C8B3-45CC-BD41-681A63023757 Q34084483-785681FC-2ED0-41AB-AF9C-359C2AEB2761 Q34222447-9B63D328-4AD5-41CF-892C-AF4B4A0F58B4 Q34510512-18F94470-93CD-4783-B0A3-166BA15129AE Q34989162-4736A939-A4BF-418C-A1D8-62FAAB8F01AE Q35721537-59897DFE-AA92-497C-B05D-ACCE67E19AA5 Q36105637-E3871DE4-44F3-4ADC-8897-B5C5A97E957D Q37662616-9598F444-3E77-4835-9235-F9704F99482D Q38050879-8250CB01-B9AB-470B-B736-921293217BC8 Q38800987-648AED74-E5F2-40A0-A1B4-24BF0BE1A85A Q39375492-CC8D9349-B641-47B9-AB83-4F0A521C1216 Q39594232-BBD26D8E-9D52-4428-9B82-0ACE0E6EEDF9 Q43240077-89FC68FE-8614-4B2D-B872-FF39986D9F3E

P2860

Optimization of conventional therapy in patients with IBD.

http://www.wikidata.org/entity/Q37942292

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimization of conventional therapy in patients with IBD.

@en

Optimization of conventional therapy in patients with IBD.

@nl

type

label

Optimization of conventional therapy in patients with IBD.

@en

Optimization of conventional therapy in patients with IBD.

@nl

prefLabel

Optimization of conventional therapy in patients with IBD.

@en

Optimization of conventional therapy in patients with IBD.

@nl

P1433

Q37942292-F37B2BC0-7EBB-45A0-B771-77BF5189AB19

P1476

Q37942292-242A201D-742A-4091-899D-7115C52163C0

P2093

Q37942292-569CA5CC-046D-4E46-A4FD-DCDCA82FADA0

Q37942292-F2108337-0B73-46B9-86C3-D1F9EC82DCE2

P2860

Q37942292-02A2A31B-DE77-4002-A0CD-1EF777BB8628

Q37942292-085EFAC1-42BE-433C-B08D-39AC04A32DDB

Q37942292-0D3094ED-56EE-42A5-947D-C61195CC87AB

Q37942292-194A01CF-B9A7-4588-9BE1-262448052B0A

Q37942292-1960BEC1-440D-448E-AFDE-56BE613935C3

Q37942292-1F302CFE-75CE-40EA-8CA3-A9512A830E78

Q37942292-1FC49278-B96D-41B1-87E5-4FA7DAAE9CBC

Q37942292-23AF2ADB-80FC-4A27-9559-3710914A65D1

Q37942292-26E20577-4B0E-4CD2-B187-FD422F1F4887

Q37942292-27885250-709E-4E65-BD88-206A7C20AB8E

P2888

Q37942292-799284CE-EC25-4389-B87A-321BD7E505BD

P304

Q37942292-4D45F510-4252-4048-B6A4-A8BA6B22C1F3

P31

Q37942292-4D545A1C-2178-4A07-8087-EE1DB9BDBC94

P356

Q37942292-F5E934EA-A342-4000-84C8-03D924FAD834

P407

Q37942292-B56B821A-073C-47CE-8A90-0132C4E095FB

P433

Q37942292-FF2763BA-14FD-4428-AE27-F71758F15488

P478

Q37942292-08E44E2B-6EC8-40CA-82B1-467B0A117CFA

P577

Q37942292-AF53A414-1268-4F25-B522-85BD0BF63B70

P698

Q37942292-6129A2E0-76D7-465E-907A-3D1906F6CD27

P356

NRGASTRO.2011.172

P1433

Nature Reviews Gastroenterology & Hepatology

P1476

Optimization of conventional therapy in patients with IBD.

@en

P2093

Kirstin M Taylor

http://www.w3.org/2001/XMLSchema#string

Peter M Irving

http://www.w3.org/2001/XMLSchema#string

P2860

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

Efficacy of parenteral methotrexate in refractory Crohn's disease.

Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.

Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer.

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

P2888

nrgastro.2011.172

P304

646-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRGASTRO.2011.172

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21970871

http://www.w3.org/2001/XMLSchema#string